Few effective treatments are available for male pattern hair loss (MPHL) or, especially, for female pattern hair loss (FPHL). Recently, cell-based therapies using autologous or allogeneic cells have been used clinically.
We examined the safety and efficacy of autologous cell–based therapy using dermal sheath cup (DSC) cells to treat MPHL and FPHL.
DSCs dissected from occipital hair follicles were cultured to manufacture DSC cells. Participants with MPHL or FPHL received single injections of 7.5 × 106, 1.5 × 106, or 3.0 × 105 DSC cells or a placebo in 4 randomized separate regions on the scalp, and hair densities and diameters were measured for 3, 6, 9, and 12 months.
Fifty men and 15 women aged 33 to 64 years were injected with DSC cells. Total hair density and cumulative hair diameter at the 3.0 × 105 DSC cells injection site was significantly increased compared with the placebo after 6 and 9 months. Men and women showed similar improvements, and there were no serious adverse events.
No lower cell numbers were tested, and the positive effect was temporary until 9 months.
The results suggest that cell therapy with autologous DSC cells may be useful as a new therapeutic method for treating MPHL and FPHL.Le texte complet de cet article est disponible en PDF.
Key words : dermal sheath cup cells, cell-based therapy, regenerative medicine, hair regrowth, male pattern hair loss, female pattern hair loss, androgenetic alopecia
Abbreviations used : ALP, DP, DSC, FPHL, MPHL, PHL
| Funding sources: Supported by Shiseido Co., Ltd., Japan
| Conflicts of interest: None disclosed.
| IRB approval status: Reviewed and approved by the Tokyo Medical University Hospital IRB (approval no. 115), the Toho University Ohashi Medical Center IRB (approval no. 14-44), and the Certified Committee for Regenerative Medicine at Tokyo Medical University (approval no. 2016001).